"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04339504","Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose)","Change of total score in WOMAC (Western Ontario and McMaster University)|Change of score in WOMAC three subscales (Pain, stiffness, physical function)|Change of score in 100 mm VAS (Visual Analogue Scale)|Change of score in IKDC(International Knee Documentation Committee)|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)|Change in K&L(Kellgren-Lawrence) grade|Change in joint space width|Change in mechanical axis, anatomical axis|Rate of surgery to treat application site after treatment of SMUP-IA-01|Changes in biomarker","Medipost Co Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-SMUP-IA-P01-F/U","April 14, 2020","December 2025","December 2025","April 9, 2020",,"August 24, 2022","Seoul national University Hospital, Seoul, Jongno-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04339504"
2,"NCT04037345","Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose)","Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment|Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment|Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline|Change of score in IKDC(International Knee Documentation Committee)compared to baseline|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment|Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment|Change in joint space width compared to the baseline at 3 months and 6 months after treatment|Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment","Medipost Co Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-SMUP-IA-01-P01","October 7, 2019","November 12, 2020","November 12, 2020","July 30, 2019",,"February 24, 2021","Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04037345"
3,"NCT05182034","Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: SMUP-IA-01(low dose)|Biological: SMUP-IA-01(mid dose)|Drug: Active Control Group Sodium chloride","Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline|Change amount of WOMAC total score at post-dose 24 weeks from the baseline|Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline|Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline|Change in T2 mapping at post-dose 52 weeks from the baseline|Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline|Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.|Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks","Medipost Co Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MP-SMUP-IA-01-P02","February 24, 2022","August 30, 2023","August 30, 2023","January 10, 2022",,"September 1, 2022","Seoul Nation University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Anam Hospita, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05182034"
